RU2003132584A - Эритропоэтин облегчает in vivo токсичность, индуцированную химиотерапией - Google Patents
Эритропоэтин облегчает in vivo токсичность, индуцированную химиотерапией Download PDFInfo
- Publication number
- RU2003132584A RU2003132584A RU2003132584/14A RU2003132584A RU2003132584A RU 2003132584 A RU2003132584 A RU 2003132584A RU 2003132584/14 A RU2003132584/14 A RU 2003132584/14A RU 2003132584 A RU2003132584 A RU 2003132584A RU 2003132584 A RU2003132584 A RU 2003132584A
- Authority
- RU
- Russia
- Prior art keywords
- toxicity
- units
- combinations
- administered
- chemotherapy
- Prior art date
Links
- 230000001988 toxicity Effects 0.000 title claims 6
- 231100000419 toxicity Toxicity 0.000 title claims 6
- 238000002512 chemotherapy Methods 0.000 title claims 5
- 238000000034 method Methods 0.000 claims 17
- 239000002246 antineoplastic agent Substances 0.000 claims 7
- 102000003951 Erythropoietin Human genes 0.000 claims 6
- 108090000394 Erythropoietin Proteins 0.000 claims 6
- 229940127089 cytotoxic agent Drugs 0.000 claims 6
- 239000002254 cytotoxic agent Substances 0.000 claims 6
- 231100000599 cytotoxic agent Toxicity 0.000 claims 6
- 229940105423 erythropoietin Drugs 0.000 claims 6
- OXCMYAYHXIHQOA-UHFFFAOYSA-N potassium;[2-butyl-5-chloro-3-[[4-[2-(1,2,4-triaza-3-azanidacyclopenta-1,4-dien-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol Chemical compound [K+].CCCCC1=NC(Cl)=C(CO)N1CC1=CC=C(C=2C(=CC=CC=2)C2=N[N-]N=N2)C=C1 OXCMYAYHXIHQOA-UHFFFAOYSA-N 0.000 claims 6
- 206010061924 Pulmonary toxicity Diseases 0.000 claims 4
- 231100000374 pneumotoxicity Toxicity 0.000 claims 4
- 230000007047 pulmonary toxicity Effects 0.000 claims 4
- YJGVMLPVUAXIQN-LGWHJFRWSA-N (5s,5ar,8ar,9r)-5-hydroxy-9-(3,4,5-trimethoxyphenyl)-5a,6,8a,9-tetrahydro-5h-[2]benzofuro[5,6-f][1,3]benzodioxol-8-one Chemical compound COC1=C(OC)C(OC)=CC([C@@H]2C3=CC=4OCOC=4C=C3[C@@H](O)[C@@H]3[C@@H]2C(OC3)=O)=C1 YJGVMLPVUAXIQN-LGWHJFRWSA-N 0.000 claims 2
- 108010006654 Bleomycin Proteins 0.000 claims 2
- DLGOEMSEDOSKAD-UHFFFAOYSA-N Carmustine Chemical compound ClCCNC(=O)N(N=O)CCCl DLGOEMSEDOSKAD-UHFFFAOYSA-N 0.000 claims 2
- 102000015696 Interleukins Human genes 0.000 claims 2
- 108010063738 Interleukins Proteins 0.000 claims 2
- 229930192392 Mitomycin Natural products 0.000 claims 2
- NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 claims 2
- 229940122803 Vinca alkaloid Drugs 0.000 claims 2
- 150000008052 alkyl sulfonates Chemical class 0.000 claims 2
- 239000003242 anti bacterial agent Substances 0.000 claims 2
- 230000003115 biocidal effect Effects 0.000 claims 2
- 229960001561 bleomycin Drugs 0.000 claims 2
- OYVAGSVQBOHSSS-UAPAGMARSA-O bleomycin A2 Chemical group N([C@H](C(=O)N[C@H](C)[C@@H](O)[C@H](C)C(=O)N[C@@H]([C@H](O)C)C(=O)NCCC=1SC=C(N=1)C=1SC=C(N=1)C(=O)NCCC[S+](C)C)[C@@H](O[C@H]1[C@H]([C@@H](O)[C@H](O)[C@H](CO)O1)O[C@@H]1[C@H]([C@@H](OC(N)=O)[C@H](O)[C@@H](CO)O1)O)C=1N=CNC=1)C(=O)C1=NC([C@H](CC(N)=O)NC[C@H](N)C(N)=O)=NC(N)=C1C OYVAGSVQBOHSSS-UAPAGMARSA-O 0.000 claims 2
- 229960005243 carmustine Drugs 0.000 claims 2
- YJGVMLPVUAXIQN-UHFFFAOYSA-N epipodophyllotoxin Natural products COC1=C(OC)C(OC)=CC(C2C3=CC=4OCOC=4C=C3C(O)C3C2C(OC3)=O)=C1 YJGVMLPVUAXIQN-UHFFFAOYSA-N 0.000 claims 2
- 150000002224 folic acids Chemical class 0.000 claims 2
- 229960004857 mitomycin Drugs 0.000 claims 2
- OSTGTTZJOCZWJG-UHFFFAOYSA-N nitrosourea Chemical compound NC(=O)N=NO OSTGTTZJOCZWJG-UHFFFAOYSA-N 0.000 claims 2
- 206010029350 Neurotoxicity Diseases 0.000 claims 1
- 231100000153 central nervous system (CNS) toxicity Toxicity 0.000 claims 1
- 231100000433 cytotoxic Toxicity 0.000 claims 1
- 230000001472 cytotoxic effect Effects 0.000 claims 1
- 230000002440 hepatic effect Effects 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 231100000417 nephrotoxicity Toxicity 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/18—Growth factors; Growth regulators
- A61K38/1816—Erythropoietin [EPO]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/17—Amides, e.g. hydroxamic acids having the group >N—C(O)—N< or >N—C(S)—N<, e.g. urea, thiourea, carmustine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/407—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with other heterocyclic ring systems, e.g. ketorolac, physostigmine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/14—Peptides containing saccharide radicals; Derivatives thereof, e.g. bleomycin, phleomycin, muramylpeptides or vancomycin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/19—Cytokines; Lymphokines; Interferons
- A61K38/20—Interleukins [IL]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P39/00—General protective or antinoxious agents
- A61P39/02—Antidotes
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Epidemiology (AREA)
- Gastroenterology & Hepatology (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Zoology (AREA)
- Toxicology (AREA)
- Neurosurgery (AREA)
- Pulmonology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Claims (17)
1. Способ уменьшения токсичности, вызванной химиотерапией у субъекта, которому вводят цитотоксический агент, включающий введение цитотоксического агента одновременно с эритропоэтином в количестве, эффективном для уменьшения токсичности, вызванной химиотерапией.
2. Способ по п.1, отличающийся тем, что указанный цитотоксический агент представляет собой противоопухолевый агент.
3. Способ по п.2, отличающийся тем, что указанный противоопухолевый агент выбран из группы, состоящей из антибиотика, нитрозомочевины, алкилсульфоната, аналога цитодина, алкалоида барвинка, эпиподофиллотоксина, интерлейкина и аналога фолиевой кислоты и их сочетаний.
4. Способ по п.2, отличающийся тем, что указанный противоопухолевый агент представляет собой блеомицин, митомицин или кармустин и их сочетания.
5. Способ по п.1, отличающийся тем, что указанная токсичность, индуцированная химиотерапией, выбрана из группы, состоящей из легочной токсичности, печеночной токсичности, токсичности ЦНС и почечной токсичности и их сочетаний.
6. Способ по п.1, отличающийся тем, что указанная токсичность, индуцированная химиотерапией, представляет собой легочную токсичность.
7. Способ по п.1, отличающийся тем, что указанный эритропоэтин вводят в количестве от около 1 ед./кг до около 2000 ед./кг.
8. Способ по п.1, отличающийся тем, что указанный эритропоэтин вводят в количестве от около 1 ед./кг до около 200 ед./кг.
9. Способ по п.1, отличающийся тем, что указанная стадия введения включает пероральное, ректальное, наружное, буккальное, вагинальное, парентеральное, местное или чрескожное введение и их сочетания.
10. Способ уменьшения легочной токсичности у субъекта, которому вводят цитотоксический агент, включающий введение цитотоксического агента одновременно с эритропоэтином в количестве, эффективном для уменьшения легочной токсичности.
11. Способ по п.10, отличающийся тем, что указанный цитотоксический агент представляет собой противоопухолевый агент.
12. Способ по п.11, отличающийся тем, что указанный противоопухолевый агент цитотоксичен для легких указанного субъекта.
13. Способ по п.11, отличающийся тем, что указанный противоопухолевый агент выбран из группы, состоящей из антибиотика, нитрозомочевины, алкилсульфоната, аналога цитодина, алкалоида барвинка, эпиподофиллотоксина, интерлейкина и аналога фолиевой кислоты и их сочетаний.
14. Способ по п.11, отличающийся тем, что указанный противоопухолевый агент представляет собой блеомицин, митомицин или кармустин и их сочетания.
15. Способ по п.10, отличающийся тем, что указанный эритропоэтин вводят в количестве от около 1 ед./кг до около 2000 ед./кг.
16. Способ по п.10, отличающийся тем, что указанный эритропоэтин вводят в количестве от около 1 ед./кг до около 200 ед./кг.
17. Способ по п.10, отличающийся тем, что указанная стадия введения включает пероральное, ректальное, наружное, буккальное, вагинальное, парентеральное, местное или чрескожное введение и их сочетания.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US28262101P | 2001-04-09 | 2001-04-09 | |
| US60/282,621 | 2001-04-09 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2003132584A true RU2003132584A (ru) | 2005-04-10 |
| RU2296563C2 RU2296563C2 (ru) | 2007-04-10 |
Family
ID=23082337
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2003132584/14A RU2296563C2 (ru) | 2001-04-09 | 2002-04-08 | Эритропоэтин облегчает in vivo токсичность, индуцированную химиотерапией |
Country Status (22)
| Country | Link |
|---|---|
| US (2) | US20020169128A1 (ru) |
| EP (1) | EP1377164B1 (ru) |
| JP (1) | JP4428924B2 (ru) |
| KR (1) | KR100885525B1 (ru) |
| CN (2) | CN100379446C (ru) |
| AT (1) | ATE399020T1 (ru) |
| AU (1) | AU2002256133B2 (ru) |
| BR (1) | BR0208727A (ru) |
| CA (1) | CA2443025A1 (ru) |
| DE (1) | DE60227244D1 (ru) |
| DK (1) | DK1377164T3 (ru) |
| ES (1) | ES2309166T3 (ru) |
| HU (1) | HUP0303838A3 (ru) |
| IL (3) | IL158155A0 (ru) |
| MX (1) | MXPA03009182A (ru) |
| NO (1) | NO20034504L (ru) |
| NZ (1) | NZ528675A (ru) |
| PL (1) | PL373361A1 (ru) |
| PT (1) | PT1377164E (ru) |
| RU (1) | RU2296563C2 (ru) |
| WO (1) | WO2002080676A1 (ru) |
| ZA (1) | ZA200307803B (ru) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| FR2686899B1 (fr) | 1992-01-31 | 1995-09-01 | Rhone Poulenc Rorer Sa | Nouveaux polypeptides biologiquement actifs, leur preparation et compositions pharmaceutiques les contenant. |
| EP1983055A1 (en) | 2000-04-12 | 2008-10-22 | Human Genome Sciences, Inc. | Albumin fusion proteins |
| PT1463751E (pt) | 2001-12-21 | 2013-08-26 | Human Genome Sciences Inc | Proteínas de fusão de albumina |
| EP1594530A4 (en) | 2003-01-22 | 2006-10-11 | Human Genome Sciences Inc | HYBRID PROTEINS OF ALBUMIN |
| KR101163683B1 (ko) * | 2003-05-12 | 2012-07-10 | 아피맥스, 인크. | 에리스로포이에틴 수용체에 결합하는 신규의 펩티드 |
| CA2525399A1 (en) * | 2003-05-12 | 2004-11-25 | Affymax, Inc. | Novel spacer moiety for poly(ethylene glycol)-modified peptide-based co mpounds |
| EP1626983B8 (en) * | 2003-05-12 | 2010-12-22 | Affymax, Inc. | Novel poly (ethylene glycol) modified erythropoietin agonists and uses thereof |
| AU2004238868B2 (en) * | 2003-05-12 | 2010-01-21 | Affymax, Inc. | Peptides that bind to the erythropoietin receptor |
| WO2006031614A2 (en) * | 2004-09-10 | 2006-03-23 | Tosk, Inc. | Reduced toxicity methotrexate formulations and methods for using the same |
| WO2006062685A2 (en) * | 2004-11-11 | 2006-06-15 | Affymax, Inc. | Novel peptides that bind to the erythropoietin receptor |
| MX2007005777A (es) * | 2004-11-11 | 2007-07-20 | Affymax Inc | Peptidos novedosos que se unen al receptor de eritropoietina. |
| US7550433B2 (en) * | 2005-06-03 | 2009-06-23 | Affymax, Inc. | Erythropoietin receptor peptide formulations and uses |
| US7919461B2 (en) | 2005-06-03 | 2011-04-05 | Affymax, Inc. | Erythropoietin receptor peptide formulations and uses |
| US8324159B2 (en) * | 2005-06-03 | 2012-12-04 | Affymax, Inc. | Erythropoietin receptor peptide formulations and uses |
| EP2057997A4 (en) * | 2006-08-22 | 2012-11-07 | Chugai Pharmaceutical Co Ltd | MEANS FOR THE PREVENTION AND / OR TREATMENT OF PERIPHERAL NEUROPATHY |
| WO2008050836A1 (fr) * | 2006-10-25 | 2008-05-02 | Ajinomoto Co., Inc. | Agent destiné à l'amélioration des effets secondaires d'un agent chimiothérapeutique |
| EP1992355A1 (en) * | 2007-05-16 | 2008-11-19 | Eberhardt Spanuth | Pharmaceutical combination medication comprising NSAIDs or cytoxic drugs |
| RU2410095C2 (ru) * | 2009-04-20 | 2011-01-27 | Государственное образовательное учреждение высшего профессионального образования "Мордовский государственный университет им. Н.П. Огарева" | Средство для повышения эффективности и снижения токсичности противоопухолевых препаратов |
| WO2016203477A1 (en) * | 2015-06-18 | 2016-12-22 | Yeda Research And Development Co. Ltd. | Conditioning protocols and use of same for tissue regeneration |
| US10695402B2 (en) | 2017-03-16 | 2020-06-30 | University Of Rochester | Erythropoietin for gastrointestinal dysfunction |
| WO2022159414A1 (en) | 2021-01-22 | 2022-07-28 | University Of Rochester | Erythropoietin for gastroinfestinal dysfunction |
Family Cites Families (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4859765A (en) * | 1983-10-17 | 1989-08-22 | Syntex (U.S.A.) Inc. | Synthetic peptide sequences useful in biological and pharmaceutical applications and methods of manufacture |
| US4863857A (en) * | 1985-03-01 | 1989-09-05 | Board Of Regents, The University Of Texas System | Polypeptide complementary to peptides or proteins having an amino acid sequence or nucleotide coding sequence at least partially known |
| NZ215865A (en) * | 1985-04-22 | 1988-10-28 | Commw Serum Lab Commission | Method of determining the active site of a receptor-binding analogue |
| IT210425Z2 (it) * | 1987-01-22 | 1988-12-30 | Erga Srl | Portachiavi con mezzo di scrittura telescopico incorporato |
| US4853871A (en) * | 1987-04-06 | 1989-08-01 | Genex Corporation | Computer-based method for designing stablized proteins |
| US4856871A (en) * | 1987-08-31 | 1989-08-15 | General Electric Company | Replaceable laser and lens assembly |
| JP2632014B2 (ja) * | 1988-03-03 | 1997-07-16 | 中外製薬株式会社 | 骨髄機能障害性貧血治療剤 |
| GB9613070D0 (en) * | 1996-06-21 | 1996-08-28 | Rowett Research Services Limit | Dietary lectins |
| US20020052309A1 (en) * | 1996-09-11 | 2002-05-02 | Athanasius A. Anagnostou | Method of treating endothelial injury |
| US6719977B1 (en) * | 1998-02-12 | 2004-04-13 | The General Hospital Corporation | Methods to potentiate cancer therapies |
| CA2372782A1 (en) * | 1999-05-11 | 2000-11-16 | Wing Cheung | Pharmacokinetic and pharmacodynamic modeling of erythropoietin administration |
| US6531121B2 (en) * | 2000-12-29 | 2003-03-11 | The Kenneth S. Warren Institute, Inc. | Protection and enhancement of erythropoietin-responsive cells, tissues and organs |
-
2002
- 2002-04-05 US US10/117,011 patent/US20020169128A1/en not_active Abandoned
- 2002-04-08 PL PL02373361A patent/PL373361A1/xx not_active Application Discontinuation
- 2002-04-08 PT PT02725577T patent/PT1377164E/pt unknown
- 2002-04-08 ES ES02725577T patent/ES2309166T3/es not_active Expired - Lifetime
- 2002-04-08 CA CA002443025A patent/CA2443025A1/en not_active Abandoned
- 2002-04-08 HU HU0303838A patent/HUP0303838A3/hu unknown
- 2002-04-08 EP EP02725577A patent/EP1377164B1/en not_active Revoked
- 2002-04-08 BR BR0208727-8A patent/BR0208727A/pt not_active IP Right Cessation
- 2002-04-08 DK DK02725577T patent/DK1377164T3/da active
- 2002-04-08 MX MXPA03009182A patent/MXPA03009182A/es active IP Right Grant
- 2002-04-08 KR KR1020037013132A patent/KR100885525B1/ko not_active Expired - Fee Related
- 2002-04-08 JP JP2002578724A patent/JP4428924B2/ja not_active Expired - Fee Related
- 2002-04-08 AU AU2002256133A patent/AU2002256133B2/en not_active Ceased
- 2002-04-08 IL IL15815502A patent/IL158155A0/xx unknown
- 2002-04-08 RU RU2003132584/14A patent/RU2296563C2/ru not_active IP Right Cessation
- 2002-04-08 AT AT02725577T patent/ATE399020T1/de not_active IP Right Cessation
- 2002-04-08 DE DE60227244T patent/DE60227244D1/de not_active Expired - Lifetime
- 2002-04-08 CN CNB028078136A patent/CN100379446C/zh not_active Expired - Fee Related
- 2002-04-08 WO PCT/US2002/011081 patent/WO2002080676A1/en active Application Filing
- 2002-04-08 CN CNA2007101533855A patent/CN101152565A/zh active Pending
- 2002-04-08 NZ NZ528675A patent/NZ528675A/en unknown
-
2003
- 2003-09-29 IL IL158155A patent/IL158155A/en not_active IP Right Cessation
- 2003-10-06 ZA ZA200307803A patent/ZA200307803B/en unknown
- 2003-10-08 NO NO20034504A patent/NO20034504L/no not_active Application Discontinuation
-
2009
- 2009-05-17 IL IL198783A patent/IL198783A0/en unknown
-
2011
- 2011-03-31 US US13/077,335 patent/US20110195046A1/en not_active Abandoned
Also Published As
| Publication number | Publication date |
|---|---|
| EP1377164B1 (en) | 2008-06-25 |
| NO20034504D0 (no) | 2003-10-08 |
| ES2309166T3 (es) | 2008-12-16 |
| JP4428924B2 (ja) | 2010-03-10 |
| IL158155A (en) | 2009-12-24 |
| EP1377164A4 (en) | 2005-05-04 |
| MXPA03009182A (es) | 2004-02-17 |
| EP1377164A1 (en) | 2004-01-07 |
| CN100379446C (zh) | 2008-04-09 |
| PT1377164E (pt) | 2008-09-30 |
| PL373361A1 (en) | 2005-08-22 |
| KR20030087064A (ko) | 2003-11-12 |
| CA2443025A1 (en) | 2002-10-17 |
| NZ528675A (en) | 2006-10-27 |
| IL198783A0 (en) | 2010-02-17 |
| ATE399020T1 (de) | 2008-07-15 |
| AU2002256133B2 (en) | 2007-05-31 |
| BR0208727A (pt) | 2005-05-10 |
| RU2296563C2 (ru) | 2007-04-10 |
| HUP0303838A3 (en) | 2010-03-29 |
| WO2002080676A1 (en) | 2002-10-17 |
| ZA200307803B (en) | 2005-02-09 |
| US20020169128A1 (en) | 2002-11-14 |
| KR100885525B1 (ko) | 2009-02-26 |
| DK1377164T3 (da) | 2008-10-13 |
| IL158155A0 (en) | 2004-03-28 |
| US20110195046A1 (en) | 2011-08-11 |
| CN1499927A (zh) | 2004-05-26 |
| CN101152565A (zh) | 2008-04-02 |
| HUP0303838A2 (hu) | 2004-03-01 |
| NO20034504L (no) | 2003-12-09 |
| JP2004532840A (ja) | 2004-10-28 |
| DE60227244D1 (de) | 2008-08-07 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2003132584A (ru) | Эритропоэтин облегчает in vivo токсичность, индуцированную химиотерапией | |
| Stein | Pharmacokinetics and pharmacodynamics of newer fluoroquinolones | |
| JP2004501964A5 (ru) | ||
| CA2422711A1 (en) | Inhibition of emetic effect of metformin with 5-ht3 receptor antagonists | |
| LUC00155I1 (ru) | ||
| BR0010783A (pt) | Novos compostos, seu uso e preparação | |
| LU92323I2 (fr) | La combinaison de (a) dextromethorphan ou un de ses sels pharmaceutiquement acceptables, précursers ou dérivés, par ex. hydrobromure de dextromethorphan et en particulier hydrobromure de dextromethorphan monohydrate;et (b) quinidine ou un de ses selspharmacuetiquement acceptables, précurseurs ou dé rivés, par ex. sulfate de quinidine et en particulier sulfate de quinidine dihydrate | |
| TW200635930A (en) | Bicyclic pyrrole derivatives | |
| CA2176604A1 (en) | Lactone stable formulation of 10-hydroxy 7-ethyl camptothecin | |
| BG105810A (en) | Camptothecin derivatives having antitumor activity | |
| AR015768A1 (es) | DERIVADOS DE IMIDAZO PIRIDINA QUE INHIBEN LA SECRECIoN DE ÁCIDO GÁSTRICO, COMPOSICIoN FARMACÉUTICA, PROCEDIMIENTOS PARA SU PREPARACIoN, FORMULACIoN FARMACÉUTICA, USO DE DICHOS DERIVADOS PARA PREPARAR MEDICAMENTOS Y COMPUESTOS INTERMEDIARIOS uTILES EN EL PROCEDIMIENTO PARA LA PREPARACIoN DE DICHOS DE | |
| WO2005110423A3 (en) | Pyrrolobenzodiazepine therapeutic agents useful in the treatment of leukaemias | |
| ATE548357T1 (de) | Gonadotropin freisetzende hormon rezeptor antagonisten und ihre verwandten verfahren | |
| AUPR213700A0 (en) | Antiviral agents | |
| CA2182981A1 (en) | Sublingual or buccal pharmaceutical composition | |
| BG103969A (en) | C-4"-substituted macrolide derivatives | |
| HUP9903104A2 (hu) | Piridazino[4,5-b]kinolin-5-oxid-származékok, ezek előállítása, alkalmazásuk és glicinantagonistaként ezeket tartalmazó gyógyszerkészítmények | |
| CA2146763A1 (en) | Quinolone and acridinone derivatives for the treatment of urinary incontinence | |
| EP2060255A3 (en) | Methods and compositions for prevention and treatment of inflammatory disease, autoimmune disease, and transplant rejection | |
| KR890700583A (ko) | 6,11-디하이드로-11-(4-피페리딜리덴)-5H-벤조[5,6]사이클로헵타[1,2-b]피리딘 및 조성물 및 사용방법 | |
| NO20013645D0 (no) | Anvendelse av pyridazino[4,5-b]indol-1-acetamid-derivater for fremstilling av medisiner for behandling av sykdommer relatert tildysfunksjonen av perifere benzodiazepinreseptorer | |
| WO2005026145A3 (en) | Quinolone antibacterial agents | |
| KR910015580A (ko) | 신규 콜린에스테라제 억제제로서의 삼환-일환식 아민 | |
| DK1165065T3 (da) | Slugetabletter med højt indhold af N-acetylcystein | |
| ME02544B (me) | 24-norUDCA za liječenje autoimunog hepatitisa |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20110409 |